The company said net sales for Q1 2024 were $800.5 million, down from $845.4 million a year earlier, and organic net sales fell 6%. It cited lower volumes in the Health & Science Technologies segment as the main factor.

1. 01

   The company said net sales for Q1 2024 were $800.5 million, down from $845.4 million a year earlier, and organic net sales fell 6%. It cited lower volumes in the Health & Science Technologies segment as the main factor.

2. 02

   IDEX reported net income attributable to IDEX of $121.4 million for Q1 2024 ($139.8 million a year earlier), and diluted EPS of $1.60 ($1.84 a year earlier). Adjusted diluted EPS was $1.88, compared with $2.09 a year earlier.

3. 03

   The company said operating cash flow for Q1 2024 was $156.6 million ($147.9 million a year earlier), and free cash flow was $136.6 million ($121.3 million a year earlier). It said free cash flow is operating cash flow less capital expenditures of $20.0 million.

4. 04

   IDEX said it expects organic sales growth for 2024 of 0% to 2%, and GAAP diluted EPS of $7.13 to $7.43 (adjusted $8.15 to $8.45). For Q2, it projected organic sales declines of 2% to 3% and GAAP diluted EPS of $1.75 to $1.80.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.